This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Black Diamond (BDTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Black Diamond (BDTX) points to a 153% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 129.3% in Black Diamond (BDTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%
by Zacks Equity Research
The mean of analysts' price targets for Black Diamond Therapeutics (BDTX) points to a 95.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)
by Zacks Equity Research
Black Diamond (BDTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
What's in the Cards for Doximity (DOCS) in Q2 Earnings?
by Zacks Equity Research
Doximity's (DOCS) products like Doximity Dialer and Residency Navigator have been in focus and we expect both to have generated significant revenues during the fiscal second quarter.
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
Canopy Growth's (CGC) newly-added Ace Valley and Supreme Cannabis hold part of the company's market share in fiscal Q2.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenues, and provide updates on its diversified product portfolio when it releases third-quarter 2021 results.
Is a Surprise Coming for Black Diamond Therapeutics (BDTX) This Earnings Season?
by Zacks Equity Research
Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Coupa Software's (COUP) BSM Platform Adopted by World Vision
by Zacks Equity Research
Coupa Software (COUP) is likely to benefit from coronavirus-induced robust demand for the company's BSM offering.
Coupa Software (COUP) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Coupa Software's (COUP) first-quarter fiscal 2021 results benefit from coronavirus crisis-triggered robust demand for Coupa BSM and market traction of Coupa Pay offerings.
How Black Diamond Therapeutics (BDTX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Black Diamond Therapeutics (BDTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
by Zacks Equity Research
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
5 Stocks With Recent Price Strength Amid Disappointing Data
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Black Diamond Therapeutics, Inc. (BDTX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Black Diamond Therapeutics, Inc. (BDTX).
New Strong Buy Stocks for April 27th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: